References
Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz H-U, Sjöqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27: 1673–1677
Cooper RG, Evans DAP (1984) Oxidation polymorphism has clinical relevance. Lancet 2: 227
Dayer P, Balant L, Courvoisier F, Küpfer A, Kubli A, Gorgia A, Fabre J (1982) The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 7: 73–77
Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA (1984) Characterization of a common genetic defect of cytochrome P-450 mediated function (debrisoquine-sparteine type polymorphism). Biochem Biophys Res Commun 125: 374–380
Dayer P, Leemann T, Marmy A, Rosenthaler J (1985) Interindividual variation of beta-adrenoceptor blocking drugs plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol 28: 149–153
Dengler HJ, Eichelbaum M (1977) Polymorphismen und Defekte des Arzneimittelstoffwechsels als Ursache toxischer Reaktionen. Arzneimittelforsch 27: 1836–1844
Distlerath L, Guengerich FP (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc Natl Acad Sci USA 81: 7348–7352
Gut J, Gasser R, Dayer P, Kronbach T, Catin T, Meyer UA (1984) Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P-450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett 173: 287–290
Hori R, Okumura K, Inui KI, Yasuhara M, Yamada K, Sakurai T, Kawai C (1984) Quinidine-induced rise in ajmaline plasma concentration. J Pharm Pharmacol 36: 202–204
Idle JR, Smith RL (1984) The debrisoquine hydroxylation gene: a gene of multiple consequence. In: Lemberger L, Reidenberg M (eds) Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics. ASPET, Bethesda, pp 148–164
Leemann T, Dayer P, Balant L, Buri P (1984) Direct determination of R- and S-metoprolol in biological fluids by ion-pair-HPLC. Experientia 40: 647
Lennard MS, Silas JH, Freestone S, Threvethick J (1982) Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 14: 301–303
Lennard MS, Silas JH, Freestone S, Tucker GT, Ramsay LE, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 16: 586P-587P
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586
Meyer UA (1984) The clinical pharmacology of cytochrome P-450. In: Lemberger L, Reidenberg M (eds) Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics. ASPET, Bethesda, pp 331–341
Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73–80
Price-Evans D, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leemann, T., Dayer, P. & Meyer, U.A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29, 739–741 (1986). https://doi.org/10.1007/BF00615971
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00615971